TREATING

central sleep apnea

Press Releases

Respicardia Announces First U.S. Commercial Case With The remedē® System

Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch

Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea …

Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea

Company announces strategic relationship with ZOLL Medical

Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical Corporation, a leading manufacturer of medical devices and related software solutions. All of Respicardia’s existing major investors helped to complete the financing round …

Respicardia’s remedē® System Receives FDA Approval

Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available

Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its remedē® System, a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore natural breathing during sleep in patients with central sleep apnea …

MEDIA KIT

Find media assets, tools and templates:

Go to Media Kit

For media inquiries please contact +1-952-540-4470

Am I a candidate
for remedē®?
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

CLOSE

For Patients

IMPORTANT SAFETY INFORMATION

The remedē® System is indicated for moderate to severe Central Sleep Apnea in adult patients.

Your doctor will need to evaluate your condition to determine if the remedē system is right for you. You will not be able to have an MRI or diathermy (special heat therapies) if you have the remedē system implanted. The remedē system may be used if you have another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting.

As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection.

Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The remedē system may not work for everyone. There are additional risks associated with removing your system. If you and your doctor decide to remove the system, another surgery will be required.

Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with the implantation of the remedē system. Rx only. For further information, please call +1-952-540-4470 or email info@respicardia.com.